In this blog, Leonardo provides 5 interpretations that you should consider when you read or hear about a reported association in observational studies.
This is the nineteenth blog in a series of 36 blogs explaining 36 key concepts we need to be able to understand to think critically about treatment claims.
People in treatment comparisons who are not followed up to the end of the study may have worse outcomes than those who are followed up. For example, they may have dropped out because the treatment was not working or because of side effects. If those people are excluded, the findings of the study may be misleading.
Is evidence-based medicine a fairy tale? With this in mind, Foo Wee brings her personal experience into a review of the evidence available for analgesic treatment of G6PD deficient children. This blog won 2nd prize in the recent Cochrane Malaysia blog writing competition.
In this blog, Kamal Pandit discusses the findings of three recent Cochrane reviews which assessed the effectiveness of treatments for Coronary heart disease (CHD). He adds personal experience to provide context to treatment of a condition which is the single leading cause of death globally (WHO 2014).
This blog provides a detailed overview of the Delphi Technique, a method of congregating expert opinion through a series of iterative questionnaires, with a goal of coming to a group consensus. It covers what it is, the process involved, pros and cons and when you would consider using it.
This is the eighteenth blog in a series of 36 blogs explaining 36 key concepts we need to be able to understand to think critically about treatment claims.
If an outcome is measured differently in two comparison groups, differences in that outcome may be due to how the outcome was measured rather than because of the treatment received by people in each group. For example, if outcome assessors believe that a particular treatment works and they know which patients have received that treatment, they may be more likely to observe better outcomes in those who have received the treatment.
In this blog, Saul Crandon provides the key points to consider, advantages, disadvantages, and further details regarding intercalated degrees.
Tarang Sharma was lead-author of a recent article entitled “The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials”. In this blog, Tarang gives more details about meta-analysis methods of rare events and sparse data, and why these can lead to misleading results.
This blog, written by Leonard Goh, was the winner of Cochrane Malaysia and Penang Medical College’s recent evidence-based medicine blog writing competition. Leonard has written an insightful and informative piece to answer the question: ‘Evidence-based health practice: a fairytale or reality’.
Cochrane Malaysia and Penang Medical College, with the support of Students 4 Best Evidence (S4BE) recently ran an evidence-based medicine blog writing competition for undergraduate and postgraduate students of health in Malaysia.
This is the seventeenth blog in a series of 34 blogs explaining 34 key concepts we need to be able to understand to think critically about treatment claims.
People in a treatment group may experience improvements (for example, less pain) because they believe they are receiving a better treatment, even if the treatment is not actually better (this is called a placebo effect), or because they behave differently (due to knowing which treatment they received, compared to how they otherwise would have behaved). If individuals know that they are receiving (they are not “blinded” to) a treatment that they believe is better, some or all of the apparent effects of the treatment may be due either to a placebo effect or because the recipients behaved differently.
This is the sixteenth blog in a series of 34 blogs explaining 34 key concepts we need to be able to understand to think critically about treatment claims.
Apart from the treatments being compared, people in the treatment comparison groups should otherwise receive similar care. If, for example, people in one group receive more attention and care than people in the comparison group, differences in outcomes could be due to differences in the amount of attention each group received rather than due to the treatments that are being compared. One way of preventing this is to keep providers unaware (“blind”) of which people have been allocated to which treatment.
Alina provides a critical appraisal of the ARTEMIDA trial (2015) that assessed efficacy of Actovegin in poststroke cognitive impairment.
Cindy and Itzel provide us with a student perspective of their time at the Global Evidence Summit. It was the first meeting of Cochrane, the Campbell Collaboration, the Guidelines International Network (G-I-N), the International Society for Evidence-based Health Care and the Joanna Briggs Institute, which took place in September 2017. “…for our luck, it was our very first time attending a Colloquium. This event took place in the beautiful city of Cape Town, South Africa, the land of the first heart transplant”.